Drug profile · INN
azelastine hydrochloride
DYMISTA
azelastine hydrochloride (DYMISTA) is a histamine h1 receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — azelastine hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 1
- Data quality
- 0.89
Quick answer
azelastine hydrochloride (DYMISTA) is a histamine h1 receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is azelastine hydrochloride?
azelastine hydrochloride (DYMISTA) is a histamine h1 receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for azelastine hydrochloride?
DYMISTA is a marketed brand name for azelastine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of azelastine hydrochloride?
azelastine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.